FOR IMMEDIATE RELEASE
Tuesday, June 11, 2013
Contact: Ginny Painter, Communications Director, Marshall University Research Corporation 304-746-1964
Cancer researcher presents technology developed to help personalize chemotherapy
HUNTINGTON, W.Va. – Marshall University biomedical sciences researcher Dr. Pier Paolo Claudio traveled to a national medical meeting in Chicago earlier this month to present a technology he and his colleagues think will help physicians personalize chemotherapy for cancer treatment.
Claudio’s presentation at the annual meeting of the American Society of Clinical Oncology focused on ChemoID, a system he has developed with Marshall biology professor Dr. Jagan Valluri to measure the sensitivity of patients’ tumors to chemotherapy drugs.
“Oncologists every day face many challenges in determining the best course of therapy for an individual cancer patient,” says Claudio. “The basic problem is that patients with similar diagnoses don’t always respond to the same chemotherapy. This technology we have developed could help physicians select the appropriate chemotherapy for an individual patient—giving them an edge in the fight against cancer.”
He says ChemoID is the first chemosensitivity test for both cancer stem-like cells and bulk tumor cells.
According to Claudio, cancer stem-like cells are a small, resilient subset of cells found in tumors. Current anticancer therapies are imperfect because they target the tumor without treating the root of the cancer—the small subpopulation of these tumor-initiating cancer stem cells thought to be responsible for recurrences. The result is that the tumor often shrinks but soon grows back. In addition, the stem-like cells appear to be preferentially resistant to both standard chemotherapy and radiation treatments.
He says more evaluation of the technology is needed, but a clinical trial on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the cancer stem-like cells are evaluated.
The upshot for a cancer patient, he says, is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient’s cancer—increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
Claudio acknowledged the contributions of Dr. Anthony Alberico, chairman of the Department of Neuroscience at the university’s Joan C. Edwards School of Medicine, for providing the clinical samples, as well as his co-investigators at the school of medicine, McKown Translational Genomics Research Institute and Edwards Comprehensive Cancer Center.